DK3198009T3 - Onkolytiske tumorvira og anvendelsesfremgangsmåder - Google Patents
Onkolytiske tumorvira og anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK3198009T3 DK3198009T3 DK15843893.7T DK15843893T DK3198009T3 DK 3198009 T3 DK3198009 T3 DK 3198009T3 DK 15843893 T DK15843893 T DK 15843893T DK 3198009 T3 DK3198009 T3 DK 3198009T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- tumor viruses
- oncolytic
- oncolytic tumor
- viruses
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 230000000174 oncolytic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462054724P | 2014-09-24 | 2014-09-24 | |
PCT/US2015/051745 WO2016049201A1 (en) | 2014-09-24 | 2015-09-23 | Oncolytic tumor viruses and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3198009T3 true DK3198009T3 (da) | 2021-11-22 |
Family
ID=55581955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15843893.7T DK3198009T3 (da) | 2014-09-24 | 2015-09-23 | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
Country Status (11)
Country | Link |
---|---|
US (1) | US20170202893A1 (da) |
EP (2) | EP3198009B1 (da) |
JP (3) | JP6764859B2 (da) |
KR (2) | KR20230165385A (da) |
CN (1) | CN108064275A (da) |
AU (2) | AU2015320665B2 (da) |
CA (1) | CA2961748A1 (da) |
DK (1) | DK3198009T3 (da) |
ES (1) | ES2899913T3 (da) |
PL (1) | PL3198009T3 (da) |
WO (1) | WO2016049201A1 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
WO2016049201A1 (en) * | 2014-09-24 | 2016-03-31 | Salk Institute For Biological Studies | Oncolytic tumor viruses and methods of use |
WO2017062511A1 (en) * | 2015-10-05 | 2017-04-13 | Salk Instutitute For Biological Studies | Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration |
WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
AU2017223589B2 (en) * | 2016-02-23 | 2023-08-03 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
WO2018111767A1 (en) * | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
WO2018125970A1 (en) * | 2016-12-30 | 2018-07-05 | Salk Institute For Biological Studies | Synthetic adenoviruses targeting bone tissue and uses thereof |
MX2019008921A (es) * | 2017-01-30 | 2019-11-08 | Epicentrx Inc | Adenovirus recombinante de transgenes múltiples. |
EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
EP3773649A4 (en) * | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
AU2019251356A1 (en) * | 2018-04-09 | 2020-11-05 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
CN113710810A (zh) * | 2019-02-21 | 2021-11-26 | 安利舒免疫溶瘤技术公司 | 溶瘤腺病毒载体和使用方法 |
KR20220079551A (ko) * | 2019-09-05 | 2022-06-13 | 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 | 종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료 |
EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
KR20220153581A (ko) * | 2020-02-14 | 2022-11-18 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ulk1/2 의 억제제 및 이의 사용 방법 |
WO2022236080A2 (en) * | 2021-05-06 | 2022-11-10 | Asimov Inc. | Compositions and methods for adeno-associated viral production |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
ATE546531T1 (de) * | 2003-12-31 | 2012-03-15 | Kalobios Inc | Transaktivierungssystem für säugerzellen |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
KR101721725B1 (ko) * | 2010-08-16 | 2017-03-31 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 아데노바이러스 조립 방법 |
CN110592123A (zh) | 2012-03-13 | 2019-12-20 | 萨克生物研究学院 | 使用腺病毒和化学二聚体的选择性细胞寻靶 |
SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
US10647963B2 (en) * | 2013-04-18 | 2020-05-12 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
WO2016049201A1 (en) | 2014-09-24 | 2016-03-31 | Salk Institute For Biological Studies | Oncolytic tumor viruses and methods of use |
-
2015
- 2015-09-23 WO PCT/US2015/051745 patent/WO2016049201A1/en active Application Filing
- 2015-09-23 EP EP15843893.7A patent/EP3198009B1/en active Active
- 2015-09-23 EP EP21193392.4A patent/EP4043021A3/en active Pending
- 2015-09-23 DK DK15843893.7T patent/DK3198009T3/da active
- 2015-09-23 CA CA2961748A patent/CA2961748A1/en active Pending
- 2015-09-23 ES ES15843893T patent/ES2899913T3/es active Active
- 2015-09-23 JP JP2017515974A patent/JP6764859B2/ja active Active
- 2015-09-23 KR KR1020237040919A patent/KR20230165385A/ko not_active Application Discontinuation
- 2015-09-23 CN CN201580063723.9A patent/CN108064275A/zh active Pending
- 2015-09-23 AU AU2015320665A patent/AU2015320665B2/en active Active
- 2015-09-23 PL PL15843893T patent/PL3198009T3/pl unknown
- 2015-09-23 KR KR1020177011121A patent/KR102608590B1/ko active IP Right Grant
-
2017
- 2017-03-24 US US15/468,565 patent/US20170202893A1/en active Pending
-
2020
- 2020-09-14 JP JP2020153724A patent/JP7416423B2/ja active Active
-
2022
- 2022-05-24 AU AU2022203504A patent/AU2022203504A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216375A patent/JP2024038030A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024038030A (ja) | 2024-03-19 |
AU2022203504A1 (en) | 2022-06-09 |
PL3198009T3 (pl) | 2022-01-24 |
EP3198009A4 (en) | 2018-09-05 |
JP2017534263A (ja) | 2017-11-24 |
EP4043021A2 (en) | 2022-08-17 |
AU2015320665A1 (en) | 2017-04-06 |
EP4043021A3 (en) | 2022-11-23 |
JP7416423B2 (ja) | 2024-01-17 |
AU2015320665B2 (en) | 2022-06-16 |
KR20230165385A (ko) | 2023-12-05 |
CN108064275A (zh) | 2018-05-22 |
KR102608590B1 (ko) | 2023-12-01 |
EP3198009B1 (en) | 2021-09-08 |
ES2899913T3 (es) | 2022-03-15 |
JP2021007392A (ja) | 2021-01-28 |
US20170202893A1 (en) | 2017-07-20 |
CA2961748A1 (en) | 2016-03-31 |
KR20170063801A (ko) | 2017-06-08 |
JP6764859B2 (ja) | 2020-10-07 |
EP3198009A1 (en) | 2017-08-02 |
WO2016049201A1 (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3198009T3 (da) | Onkolytiske tumorvira og anvendelsesfremgangsmåder | |
FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
HK1248106A1 (zh) | Pd-1結合分子和其使用方法 | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
DK3400293T3 (da) | Modificeret onkolytisk virus | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3221357T3 (da) | Fælles letkæder og fremgangsmåder til anvendelse | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
PL3160498T3 (pl) | Cząsteczki na bazie IL-15 i sposoby ich zastosowania | |
DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
DK3205650T3 (da) | Egfr-hæmmer og fremstilling og anvendelse deraf | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
DK3218005T3 (da) | Glycan-interagerende forbindelser og anvendelsesfremgangsmåder | |
DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3100050T3 (da) | Immobiliserede proteiner og anvendelse deraf |